CD58

Overview

CD58 (cluster of differentiation 58), also known as LFA-3 (lymphocyte function-associated antigen 3), is a cell adhesion molecule that serves as the ligand for CD2 on T cells and NK cells. It plays a key role in immune synapse formation and antigen presentation. Somatic loss-of-function mutations in CD58 have been identified as a mechanism of immune evasion in diffuse large B-cell lymphoma (DLBCL), allowing tumor cells to escape T cell and NK cell recognition.

Alterations observed in the corpus

  • Identified as a recurrently mutated gene in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing of 55 tumors PMID:22343534
  • Homozygous deletion in 2/18 (11%) PCNSL cases; immune-evasion mechanism through loss of cell-adhesion ligand for CD2 PMID:25991819

Cancer types (linked)

  • DLBCL: Recurrent loss-of-function somatic mutations implicated in immune evasion PMID:22343534

Co-occurrence and mutual exclusivity

Therapeutic relevance

  • CD58 loss is a potential mechanism of resistance to immunotherapy and cellular therapies (e.g., CAR-T) that rely on CD2-CD58 interactions for immune synapse formation; no direct therapeutic agent reported in the corpus.

Open questions

  • The frequency and functional consequences of CD58 mutations across DLBCL subtypes (GCB vs. ABC) remain to be characterized PMID:22343534

Sources

  • PMID:22343534 — Whole-exome sequencing identifies recurrent mutations in DLBCL (Broad Institute, 55 tumors)

This page was processed by crosslinker on 2026-05-14. - PMID:25991819

This page was processed by crosslinker on 2026-05-14.